The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 16, 2025

Filed:

Apr. 24, 2020
Applicants:

University of South Florida, Tampa, FL (US);

H. Lee Moffitt Cancer Center and Research Institute Inc., Tampa, FL (US);

Inventors:

Jianfeng Cai, Tampa, FL (US);

Peng Sang, Tampa, FL (US);

Yan Shi, Tampa, FL (US);

Haitao Ji, Tampa, FL (US);

Min Zhang, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/02 (2006.01); A61K 38/08 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/02 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01);
Abstract

Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.


Find Patent Forward Citations

Loading…